The success of the 3-hydroxy-3-methylglutaryl-coenzyme
A reductase inhibitors (statins) in ameliorating
atherothrombotic events is firmly established. Large
randomised controlled clinical trials have consistently (and
unequivocally) demonstrated a beneficial role in reducing
coronary events and total mortality in patients with advanced
coronary artery disease (CAD).
Statin therapy following percutaneous coronary revascularisation: time to make LIPS stick?
July 2004Br J Cardiol (Acute Interv Cardiol) 2004;11:AIC 38–AIC 40 Leave a commentClick any image to enlarge
